Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD

Clearside Biomedical, Inc.

Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).
Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.
FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.
Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.
Tony Gibney appointed Chair of Board effective November 1, 2024.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-046085
form_type: 8-K
ticker: CLSDQ
cik: 0001539029
company_name: Clearside Biomedical, Inc.
filed_at: 2025-03-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.947984+00:00
generated_at: 2026-05-24T03:53:33.400077+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-046085
json_url: https://secwatch.observer/filing/0000950170-25-046085.json
markdown_url: https://secwatch.observer/filing/0000950170-25-046085.md
text_url: https://secwatch.observer/filing/0000950170-25-046085.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/0000950170-25-046085-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/clsd-20250327.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-046085

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.